AAP
BBIO icon

Arax Advisory Partners’s BridgeBio Pharma BBIO Stock Holding History

Arax Advisory Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.8K Buy
521
+425
+443% +$30.8K ﹤0.01% 1843
2025
Q4 		$7.34K Sell
96
-711
-88% -$46.7K ﹤0.01% 2645
2025
Q3 		$41.9K Buy
807
+437
+118% +$21.3K ﹤0.01% 1909
2025
Q2 		$16K Buy
+370
New +$13.5K ﹤0.01% 1750
2024
Q3 		– Sell
-51
Closed -$1.29K – 2625
2024
Q2 		$1.29K Buy
+51
New +$1.39K ﹤0.01% 2101

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's BBIO Position: Q1 2026 in Review

Arax Advisory Partners increased its BridgeBio Pharma (BBIO) stake by 443% in Q1 2026, buying an estimated $30.8K and bringing the position to 521 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

Arax Advisory Partners first reported a position in BBIO in Q2 2024 and has held it in 5 quarters since. The position peaked at $41.9K in Q3 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Arax Advisory Partners held 521 shares of BridgeBio Pharma worth $33.8K as of Q1 2026.
  • Arax Advisory Partners bought 425 BridgeBio Pharma shares in Q1 2026, an estimated $30.8K.
  • BridgeBio Pharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1843 holding.
  • Arax Advisory Partners first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's BridgeBio Pharma position peaked at $41.9K in Q3 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.